Nektar Therapeutics
NKTR
$57.13
$2.284.16%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 14.60% | 18.26% | -800.76% | 119.59% | 29.23% |
| Total Depreciation and Amortization | -8.41% | -49.77% | 28.31% | -66.57% | -31.94% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -320.31% | -150.23% | 103.66% | -373.24% | -481.34% |
| Change in Net Operating Assets | -183.86% | -2,352.74% | 98.73% | -1,183.25% | -90.21% |
| Cash from Operations | -6.61% | 6.76% | -6.21% | -5.13% | -16.52% |
| Capital Expenditure | -208.11% | -1,750.00% | 99.56% | 31.08% | -258.06% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -290.85% | 13.64% | 1,027.03% | -110.07% | 172.50% |
| Cash from Investing | -291.22% | 13.56% | -27.44% | 30.57% | 171.56% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 12.80% | 2,914.29% | -91.57% | 538.46% | -31.58% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 67,045.50% | 2,914.29% | -91.57% | 538.46% | -31.58% |
| Foreign Exchange rate Adjustments | -83.33% | 700.00% | -103.03% | 217.86% | -2,700.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -147.78% | 176.41% | -137.88% | 552.05% | 110.48% |